FDA says its safety review of abortion pill will continue into next year
[October 08, 2026]
By MATTHEW PERRON
WASHINGTON (AP) — The Food and Drug Administration says its ongoing
safety review of the nation's main abortion pill will continue into next
year, a timeline that was quickly condemned by abortion opponents hoping
to see the drug's use curtailed.
The FDA gave a court-ordered update on its progress in a legal filing
late Wednesday, providing the first substantive information about the
controversial reevaluation ordered by Health Secretary Robert F. Kennedy
Jr.
Mifepristone was first approved by the FDA in 2000. The agency has
repeatedly reaffirmed the pill’s safety and effectiveness over the
years, in addition to easing a number of restrictions on the drug,
including dropping a requirement that it be dispensed in person.
But since President Donald Trump returned to the White House,
anti-abortion groups and their allies in Congress have pushed the
administration to revisit the pill, in the hopes of restricting its use.
The FDA said in its filing that it expects to complete a safety study of
the pill by mid-December this year. A report on the findings is expected
“no later than March 2027,” after which the agency will decide whether
to impose new restrictions or other changes on the drug's use.
Gavin Oxley of Americans United for Life, an anti-abortion group,
criticized the move as a lack of “true leadership” by Trump
administration officials.
“The administration continues to find itself on the wrong side of
women's health, clearly uninterested in mitigating the ongoing harms
caused by the abortion pill,” Oxley said.
The two-drug regimen of mifepristone, combined with a second drug
misoprostol, is the most common form of abortion in the U.S.
The FDA was directed to provide the latest update by a federal judge in
a case brought by the state of Louisiana alleging that mail-delivery of
mifepristone undermines the state’s abortion ban. It’s one of several
state lawsuits related to mifepristone winding their way through the
courts.
[to top of second column]
|
 Last month a three-judge panel for
the 5th U.S. Circuit Court of Appeals questioned the merits of
Louisiana’s case, including whether the state had the legal standing
to challenge FDA’s oversight of mifepristone.
Any ruling from the 5th Circuit on the Louisiana case would not
immediately change the landscape because the Supreme Court has
blocked changes to the drug until it sees the case again.
The FDA said Wednesday it is using a “statistical data mining
method” to discover “unknown safety concerns,” that may exist with
the drug. The data comes from an electronic database that collects
reports of medical injuries and drug side effects from major health
networks and insurers.
In addition to the safety study, the agency said it is considering a
number of petitions proposing changes to how mifepristone is
prescribed and distributed.
Abortion opponents have focused most of their efforts on a 2021
decision allowing doctors to prescribe the drug online and send it
through the mail during COVID-19. That decision, made permanent
under President Joe Biden in 2023, had the effect of undermining a
number of state abortion bans, since women can receive the drug
through the mail.
All contents © copyright 2026 Associated Press. All rights reserved
 |
